文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

MRI引导前列腺癌格栅极量消融推量放疗的I期试验

Phase I Trial of MRI-Guided Prostate Cancer Lattice Extreme Ablative Dose (LEAD) Boost Radiation Therapy.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2020-02-19

I期试验纳入25例前列腺癌患者,对多参数MRI定义的大体肿瘤体积采用格栅极量消融技术给予12-14 Gy推量,随后全前列腺及近端精囊腺放疗至76 Gy。中位随访66个月,未出现3级急性/亚急性泌尿生殖或胃肠道不良事件,最大晚期泌尿生殖毒性以1级为主,仅1例4级。

要点

  • MRI引导格栅极量消融推量技术可行,剂量学参数达标。
  • 无3级急性/亚急性泌尿生殖或胃肠道不良事件。
  • 晚期泌尿生殖毒性1级60%、2级16%、4级4%;晚期胃肠道毒性1级44%、2级16%。

核心结论

  • 外照射联合 upfront 空间分次立体定向高剂量mpMRI-GTV推量可行,未出现非预期事件。

研究设计与样本

  • I期临床试验纳入25例低至高危前列腺癌患者,均有1至3个可疑mpMRI大体肿瘤体积。
  • 第1天对mpMRI-GTV采用剂量柱格栅极量消融技术给予12至14 Gy。
  • 随后全前列腺及近端精囊腺放疗至76 Gy,每次2 Gy。
  • 部分高危患者远端精囊腺及盆腔淋巴结同步放疗至56 Gy,每次1.47 Gy,共38次。
  • 格栅极量消融柱体积总剂量为88至90 Gy(按α/β比3计算,2 Gy等效剂量为112至123 Gy)。

主要发现

  • 剂量学参数令人满意地达标。
  • 中位随访66个月,无3级急性/亚急性泌尿生殖或胃肠道不良事件。
  • 最大晚期泌尿生殖毒性:1级15例(60%)、2级4例(16%)、4级1例(4%;治疗后经尿道电切后脓毒症)。
  • 最大晚期胃肠道毒性:1级11例(44%)、2级4例(16%)。
  • 2例患者出现生化失败。

关键数值与推荐

  • 推量照射:12至14 Gy通过剂量柱给予mpMRI-GTV。
  • 全前列腺及近端精囊腺:76 Gy,每次2 Gy。
  • 高危患者远端精囊腺及盆腔淋巴结:56 Gy,每次1.47 Gy,共38次。
  • 格栅极量消融柱体积总剂量:88至90 Gy(2 Gy等效剂量112至123 Gy,α/β比3)。

临床怎么用

  • 该技术可作为前列腺癌mpMRI-GTV的高剂量推量方案,可行性已获I期试验支持。
  • 该技术现已纳入后续II期随机试验。

局限性

  • 原文未报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: A phase I clinical trial was designed to test the feasibility and toxicity of administering high-dose spatially fractionated radiation therapy to magnetic resonance imaging (MRI)-defined prostate tumor volumes, in addition to standard treatment. METHODS AND MATERIALS: We enrolled 25 men with favorable to high-risk prostate cancer and 1 to 3 suspicious multiparametric MRI (mpMRI) gross tumor volumes (GTVs). The mpMRI-GTVs were treated on day 1 with 12 to 14 Gy via dose cylinders using a lattice extreme ablative dose technique. The entire prostate, along with the proximal seminal vesicles, was then treated to 76 Gy at 2 Gy/fraction. For some high-risk patients, the distal seminal vesicles and pelvic lymph nodes received 56 Gy at 1.47 Gy/fraction concurrently in 38 fractions. The total dose to the lattice extreme ablative dose cylinder volume(s) was 88 to 90 Gy (112-123 Gy in 2.0 Gy equivalents, assuming an α-to-β ratio of 3). RESULTS: Dosimetric parameters were satisfactorily met. Median follow-up was 66 months. There were no grade 3 acute/subacute genitourinary or gastrointestinal adverse events. Maximum late genitourinary toxicity was grade 1 in 15 (60%), grade 2 in 4 (16%), and grade 4 in 1 (4%; sepsis after a posttreatment transurethral resection). Maximum late gastrointestinal toxicity was grade 1 in 11 (44%) and grade 2 in 4 (16%). Two patients experienced biochemical failure. CONCLUSIONS: External beam radiation therapy delivered with an upfront spatially fractionated, stereotactic high-dose mpMRI-GTV boost is feasible and was not associated with any unexpected events. The technique is now part of a follow-up phase II randomized trial.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Pollack A, Chinea FM, Bossart E, et al. Phase I Trial of MRI-Guided Prostate Cancer Lattice Extreme Ablative Dose (LEAD) Boost Radiation Therapy. Int J Radiat Oncol Biol Phys. 2020. PMID: 32084522. doi:10.1016/j.ijrobp.2020.01.052

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。